Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Q-Linea

24.17 SEK

-1.57 %

Less than 1K followers

QLINEA

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.57 %
-1.85 %
-46.62 %
-46.52 %
-73.49 %
-85.00 %
-98.83 %
-99.89 %
-99.73 %

Q-Linea operates in the medical technology sector. The company specializes in research and development of instruments and consumables. The products are mainly used in the treatment of infectious diseases and blood poisoning, and include diagnostic and analytical tools, as well as basic sample handling. The technology is based on the so-called ID and AST technology. Q-Linea was founded in 2008 and is headquartered in Uppsala.

Read more
Market cap
458M SEK
Turnover
35.98K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.2.
2026

Annual report '25

30.4.
2026

Interim report Q1'26

27.5.
2026

General meeting '26

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release11/28/2025, 10:00 AM

New number of shares and votes in Q-linea AB (publ)

Q-Linea
Regulatory press release11/20/2025, 3:45 PM

Q-linea announces new organisation and changes in executive leadership team

Q-Linea
Press release11/18/2025, 12:05 PM

Q-linea announces FDA submission for expanded claims for ASTar® BC G- panel

Q-Linea

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release11/17/2025, 12:00 PM

Q-linea resolves to carry out a directed issue of shares to a guarantor in connection with the completed preferential rights issue

Q-Linea
Regulatory press release11/11/2025, 5:40 PM

Q-linea announces outcome of rights issue

Q-Linea
Regulatory press release10/22/2025, 12:30 PM

Q-linea publishes prospectus in connection with the rights issue

Q-Linea
Regulatory press release10/22/2025, 11:30 AM

Q-linea announces cost efficiency program to accelerate sales and marketing activities

Q-Linea
Regulatory press release10/21/2025, 3:00 PM

BULLETIN FROM Extraordinary GENERAL MEETING IN Q-LINEA AB (PUBL)

Q-Linea
Press release10/21/2025, 8:26 AM

Redeye: Q-linea (Q3 Review) - Sales under expectations but solid cost control

Q-Linea
Q-Linea, Audiocast, Q3'25
Webcast10/20/2025, 11:00 AM

Q-Linea, Audiocast, Q3'25

Q-Linea
Regulatory press release10/20/2025, 5:30 AM

Interim report 1 January - 30 September 2025

Q-Linea
Regulatory press release10/19/2025, 6:55 PM

Stuart Gander appointed CEO and Anders Ljunggren appointed deputy CEO of Q-linea AB

Q-Linea
Press release10/3/2025, 8:00 AM

US Trauma Center signs commercial contract

Q-Linea
Regulatory press release9/18/2025, 6:10 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN Q-LINEA AB (PUBL)

Q-Linea
Press release9/18/2025, 6:05 AM

Q-linea | Letter from the CEO

Q-Linea
Regulatory press release9/18/2025, 6:00 AM

Q-linea resolves to carry out a rights issue of approximately SEK 322 million and announces terms

Q-Linea
Regulatory press release9/10/2025, 5:51 PM

Update on ESTAR tender for rapid AST

Q-Linea
Press release9/5/2025, 8:00 AM

Q-linea to initiate new clinical evaluations of ASTar in the GCC region

Q-Linea
Regulatory press release7/31/2025, 6:30 AM

New number of shares and votes in Q-linea AB (publ)

Q-Linea
Press release7/29/2025, 2:00 PM

BLASTID and Q-linea announce collaboration and conference presentation

Q-Linea
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.